A Review of the Antibacterial, Fungicidal and Antiviral Properties of Selenium Nanoparticles

Abstract

The resistance of microorganisms to antimicrobial drugs is an important problem worldwide. To solve this problem, active searches for antimicrobial components, approaches and therapies are being carried out. Selenium nanoparticles have high potential for antimicrobial activity. The relevance of their application is indisputable, which can be noted due to the significant increase in publications on the topic over the past decade. This review of research publications aims to provide the reader with up-to-date information on the antimicrobial properties of selenium nanoparticles, including susceptible microorganisms, the mechanisms of action of nanoparticles on bacteria and the effect of nanoparticle properties on their antimicrobial activity. This review describes the most complete information on the antiviral, antibacterial and antifungal effects of selenium nanoparticles.

1. Introduction

Despite the high level of medical development, microbial infections remain a significant factor in morbidity and mortality worldwide [1]. Sepsis and septic shock alone account for approximately 30 million clinical cases each year worldwide, of which 6 million are fatal [2]. The development of bacterial resistance to antibiotics is not a new problem and dates back to the 1940s–1960s [3,4]. Resistant microorganisms have a significant impact on human life and economic activity. Antibiotic-resistant bacteria significantly increase the risk of complications and death from bacteremia [1,5].

In addition, antibiotic-resistant bacteria complicate the course of foodborne illness, which accounts for more than a million deaths and 2 billion hospitalizations worldwide over a period of 20 years [6]. Complications of bacterial infections can affect almost all human tissues, organs and systems: gastrointestinal tract (gastritis, stomach ulcer, severe forms of diarrhea), central nervous system (meningitis, encephalitis), kidneys, liver, spleen, musculoskeletal system (reactive arthritis), cardiovascular system (endocarditis) and reproductive system (premature birth, stillbirth) [7,8,9,10,11,12,13]. By 2050, microbial resistance is predicted to cause a decrease in the total population of the Earth by 100–440 million people [14].

Apart from humans, antibiotic-resistant bacteria infect animals and plants, reducing the efficiency of agriculture [15,16,17]. Expected financial losses from antibiotic-resistant bacteria in 2025–2050 could be $85 trillion in GDP and $23 trillion in global trade [18]. The mechanisms of antibiotic resistance include enzymatic modification and inactivation of the antibiotic: hydrolysis, phosphorylation, glycosylation, etc. [19], reduction of cell wall permeability due to lipopolysaccharides or lipid enrichment, and removal of antibiotics from cells using special molecular pumps (multidrug [MDR] efflux pumps) [20].

In addition to bacterial antibiotic resistance, the development of fungal resistance to antifungal drugs is worth noting [21]. More than 300 million severe fungal infections have been registered in the world, of which over a million are fatal [22]. Additionally, the demand for antiviral drugs is increasing, in connection with the resistance of viruses, as well as in connection with the SARS-COV-2 pandemic [23], which affected all countries from 2019 until now. One of the promising ways to solve the problem of microbial resistance is the use of nanotechnology [24,25,26,27]. Antimicrobial nanomaterials operate through disruption of the electron transport chain [28,29], membrane destruction [30], cell division arrest [31], etc., and have garnered considerable attention due to their broad, potent and persistent bactericidal activities.

Unfortunately, recent data indicate the possibility of bacterial resistance to metal NPs and metal oxides [32,33,34,35,36,37,38,39]. Bacterial defense mechanisms include increased flagellin expression for NP sorption as well as pigment release to inactivate metal ions and activation of antioxidant defenses to combat oxidative stress [40,41,42]. Currently, an active search is underway for NPs with antibacterial properties among the nonmetallic chemical elements [33,43,44,45].

Selenium nanoparticles are one such type of nanoparticle. The study of their antimicrobial properties is a young branch of science: the vast majority of research papers (>95%) have been published in the last 10 years. According to PubMed NCBI (https://pubmed.ncbi.nlm.nih.gov/ accessed on 15 May 2023), more than 220 papers have been published with the keywords “selenium nanoparticles antimicrobial activity”, approximately 150 papers with the keywords “selenium nanoparticles antibacterial activity”, approximately 30 papers with the keywords “selenium nanoparticles antifungal activity” and approximately 20 papers with the keywords “selenium nanoparticles antiviral activity” (see Figure 1). It is important to note that every year, an increasing number of researchers pay attention to this problem. Over the past few years, research publication activity worldwide on SeNP antimicrobial properties has been growing by approximately 25–30% per year. Over 100 articles were published in 2022.

The reality of our days is the resistance of microorganisms (bacteria, fungi and viruses) to modern antibiotic, antifungal and antiviral drugs. Today, the scientific community is faced with the task of searching for new potential molecular structures to solve the problem of therapy in bacterial, fungal and viral pathogenesis. Selenium nanoparticles act as such antimicrobial agents. These nanoparticles have a fairly wide range of applications in the biomedical industry. For example, they can affect the activity of neutrophils: this immunomodulatory property of selenium nanoparticles can potentially be used in the treatment of cancer and other diseases associated with inflammation [46]. Moreover, selenium nanoparticles have a cytoprotective effect on the cells of the cerebral cortex under conditions of ischemia/reoxygenation [47]. The mechanism of action of this effect is based on the fact that nanoparticles regulate the expression of protective proteins in the cells of the cerebral cortex and reduce the total level of Ca²⁺ ions. The combination of selenium nanoparticles with the flavonoid taxifolin makes it possible to increase the neuroprotective effect in the cells of the cerebral cortex under conditions of ischemia/reoxygenation [48]. Beyond the immunomodulatory and neuroprotective effects, selenium nanoparticles also demonstrate anticancer effects. Selenium-sorafenib nanocomplexes showed better anticancer effects on HepG2 hepatic carcinoma cells than pure sorafenib [49]

According to patent searches and recent publications, SeNPs may have the several potential commercial applications (Figure 2).

The first application is the development of nutritional supplements for humans and veterinary needs [50]. It is noteworthy that SeNPs provide a more dosed supply of Se to the body compared to alternative sources, such as selenium cysteine. In particular, SeNPs, when administered orally to mice, causes less pronounced toxicity (survival is 4.5–5 times higher) and liver failure compared with the same amount of selencysteine also administered orally [51]. SeNPs can also be used in veterinary medicine as immunomodulatory agents. A drug based on nonspecific IgG/SeNPs for the correction of immunization in veterinary use did not have acute toxicity to laboratory mice [52].

The second application is the development of a test system for virus detection, for example, a test strip for the detection of anti-SARS-CoV-2 IgM and IgG in human serum and blood [53,54].

The third application is the creation of antimicrobial coatings for medical devices and personal care products [55,56]. Polyurethane/SeNP and polyvinylchloride/SeNP composites (polymers with NP coatings) inhibited the growth of bacteria Staphylococcus aureus, Staphylococcus epidermidis, Pseudomonas aeruginosa, Staphylococcus aureus, Escherichia coli, Streptococcus pneumoniae, etc., and fungi Cryptococcus neoformans, S. cerevisiae, Rhodotorula rubra, C. albicans, etc. [57,58]. The development of dressings and bandaging materials based on SeNPs to accelerate infected wound healing is also possible [59,60,61]

The fourth application is cancer prevention and treatment [62]. Anticancer drugs based on SeNPs cause the generation of ROS, which cause ER stress and the development of mitochondrial dysfunction. These processes enhance apoptosis of tumor cells [51,63]. Typically, to improve anticancer properties, SeNPs are functionalized with polymers or other biological antigens: arabinogalactans against A549 and MCF-7 cells (apoptosis induction), HepG2, polysaccharide–protein complexes (MCF-7 apoptosis induction), Ru(II)thiol/SeNPs (suppress tumor growth and angiogenesis) and polyethylenimine with folic acid [64,65,66]. The accuracy of delivery is ensured by a higher level of expression of folic acid receptors on cancer cells of most forms of cancer compared with normal human cells (for example, HepG2) [67,68]. Hyaluronic acid (A549 cells), ATP (depletion of mitochondrial membrane potential and oxidative stress) and other agents were also described [69,70]. The addition of anticancer agents (sorafenib) to SeNPs significantly increases the activity of others against aggressive cancer lines (increased calcium entry, ER stress and apoptosis of HepG2, gliablastoma A-172) [49,71,72]. Oridoni/SeNP composites have anticancer activity and reduce the viability of RAW264.7, KYSE-150 and EC970 cancer cells by ~50% [73].

The fifth application is the production of cosmeceuticals and nano-cosmeceuticals for skin, hair, nail and lip care and protection from wrinkles, photoaging, hyperpigmentation, dandruff and hair damage [74]. Selenium-containing cosmetics are developed and produced by Riga Stradins University, Phyto-C company (Newark, New York, USA), Cytolnat^® (Paris, France), etc.

The sixth application is the production of nanoparticle fertilizers for crop production and soil health. Trichoderma-harzianum-culture-biosynthesized SeNPs (60 nm) reduced Fusarium beadium and Alternaria albicans growth, and fumonisin and Alternaria toxin production, in wheat crops [75]. The addition of selenium or its compounds (usually selenites, selenates, Se-methlyselenocysteine-containing peptides, etc.) to the soil is a common practice in agriculture [76]. All of these compounds are easily soluble and can quickly be washed out of the soil; no more than 20% of the initial selenium is retained for the next farming cycle [77]. The use of SeNPs should provide a longer and dosed supply of Se to the soil. It has been shown that the addition of 1 μg/L SeNPs to the soil improves seed germination and accelerates the growth of the radish Raphanus sativus, eggplant Solanum melongena, cucumber Cucumis sativus, tomato S. lycopersicum, and chilli pepper Capsicum annuum [78,79]. Selenium fertilizers are already commercially available, at least from the Yara company (https://www.yara.co.uk/crop-nutrition/fertiliser/yara-booster-range/ accessed on 20 June 2023). The mineral composition contains SeNPs, Ca(OH)₂NPs and oxidized steel nanoparticles and can be used to improve the condition of fruit plants during periods of drought [80]. Agricultural uses may also include protecting plants from insect larvae. There is evidence of larvicidal activity of SeNPs [81]. SeNPs can be also used in the development of heavy metal and hydrogen peroxide sensors for agriculture [82,83,84].

The seventh application is the development of drugs for the treatment of inflammatory diseases (for example, recovery from a stroke) or diabetes [85,86]. In particular, it was shown that Protein/SeNPs inhibited hydroxyl radical productions in vitro [87]. Cystein/SeNPs inhibited hyperglycemia-induced ROS production in HUVEC by 40–50% [88]. Data on preclinical trials of a drug for the treatment of DM2T based on liposomes containing SeNPs have been published [89] (

Table 1. Examples of recent patents on SeNPs.

№	Patent ID	Patent Name	Reference
1	US9624237B2	Oridonin functionalized selenium nanoparticles and method of preparation thereof	[73]
2	US8445026B2	Selenium nanoparticles with improved biological effects	[90]
3	US10807920B2	Trichoderma-derived selenium nanoparticle foliar fertilizer for reducing crop fungal diseases and toxic contamination	[75]
4	US9259005B2	Antipathogenic surfaces having selenium nanoclusters	[57]
5	CN111214460A	Folic acid-chitosan-nano-selenium tumor-targeted drug delivery system and preparation method thereof	[67]
6	RU2798268C1	Method of obtaining a veterinary drug based on non-specific immunoglobulins and colloidal particles of selenium for the correction of the immune system	[52]
7	JP2011501977A	Method for producing hydrous tissue paper having antibacterial and antifungal functions	[56]
8	KR101120635B1	Method for cultivating high quality and functional vegetable fruit	[80]
9	US20220339187A1	Protein-bound nano-selenium and preparation method and application method thereof	[91]
10	US10875235B2	Bactericidal surface patterns	[58]

).

Other popular non-metal nanoparticles are SiNPs. SiNPs have a number of interesting advantages [92,93].

The first advantage is cheap synthesis. SiNPs are synthesized by the microemulsion method in the presence of oils or by the Stobers method, which requires relatively available reagents [94,95]. SiNPs can also be synthesized by a mechanochemical method, while the raw material for the synthesis of SeNPs can be river sand [96].

The second advantage is a wide range of applications, including targeted drug delivery with very high specificity [97,98,99], bioimaging [100,101,102], the creation of sensors for the detection of glucose, narcotic substances, or nucleic acids [103,104,105], the up-conversion of light (improved photosynthesis processes in agricultural plants), the protection of cereals from drought [106], and the creation of materials with antibacterial properties. SiNPs have the ability to significantly modify the surface and composition to create SiNP-based nanocomposites with antimicrobial properties [107,108,109].

The third advantage is the practically absent toxicity against eukaryotic cells. Oral administration of 1000–2000 mg/kg SiNPs did not have toxic effects in in vivo experiments and did not cause damage to internal organs in rats [110,111].

The disadvantages of SiNPs include the complexity/high cost of surface modification or the addition of metal NPs and the difficulty of obtaining SiNPs with uniform characteristics [93]. As a rule, precious-metal NPs and/or modification by several agents at once are required [104,108,109]. Antimicrobial properties have not been described for SiNPs without surface modification or addition of metal NPs [92]. SeNPs have been described as having their own antimicrobial properties [112,113,114]. In addition, modified SeNPs with antimicrobial properties can be obtained by biosynthesis, which significantly reduces the cost of their production [115,116,117].

Recently, a series of reviews has been published on the antibacterial, antifungal, anticancer, antiviral and antiparasitic properties of SeNPs [118,119,120]. It should be noted that in these works, the main emphasis is on a detailed description of the antimicrobial mechanisms of SeNPs and the contribution of conjugates to the properties of SeNPs. However, the numerical dependences of the properties of SeNPs—n particular, their size and method of preparation—are described to a lesser extent. In addition, it remains unknown to what extent the “size-antimicrobial-property” dependences of SeNPs are preserved when moving from one type of microorganism to another.

In this literature review, we aimed to analyze the dependence of the antimicrobial effect of selenium nanoparticles on their size, features of synthesis and microorganism species such as viruses, bacteria and fungi. There is no doubt that the relevance of this topic is great.

2. Synthesis Methods of Selenium Nanoparticles

In this subsection, we discuss various methods for the synthesis of selenium nanoparticles. SeNPs can be synthesized using a wide range of methods: sonochemical, reflux, microwave, hydrothermal, gamma irradiation, pulsed laser ablation, physical evaporation and “green synthesis” (biological reduction) (Figure 3). The most common method for selenium nanoparticle synthesis is chemical reduction [114]. The most commonly used precursors are SeO₂, Na₂SeO₃, NaHSeO₃ and H₂SeO₃ [121,122,123,124]. Less-common precursors are H₂Se, Na₂SeO₄, SeCl₄ or cyclo-octeno-1,2,3-selenadiazole [125,126,127,128].

As stabilizers, substances such as polysaccharides, quercetin, gallic and ascorbic acids and polyvinyl alcohol are used [129]. In addition to the stabilizer, a reducing agent (or reducer) is added to the solution, such as potassium tetrahydroborate (KBH₄), ascorbic acid, hydrazine chloride, hydrazine hydrate (N₂H₄∙3H₂O) or dimethylsulfoxide (C₂H₆OS) [130]. Sometimes substances of biological origin, mainly plant extracts, are used as reducing agents. This method of synthesis is called biological reduction [131,132]. The sonochemical method is a type of chemical reduction method in which the formation of metal NPs is formed by mixing soluble salts that react with each other to form a precipitate. Ultrasound accelerates of sediment formation. For exposure, a Ti tip immersed in a salt solution is used. It is noteworthy that, during precipitation in the presence of organic compounds, it is possible to obtain conjugated NPs [133]. The hydrothermal method is based on the reduction of inorganic precursors of SeNPs (Na₂SO₃) in aqueous solutions in the presence of organic reducing agents (for example, L-ascorbate) at an elevated temperature (~90 °C). An elevated temperature is necessary to accelerate the Se reduction reaction [134]. The reflux method is a variant of the chemical reduction method that occurs when the reaction mixture is boiled for a long time, which makes it very similar to the hydrothermal method. To increase the boiling time, a special unit with a refrigerant is used to condense the solvent vapors and return them to the reaction mixture [135]. The microwave method for the synthesis of nanoparticles is based on the reduction reaction of selenium-containing precursors in a medium with a reducing agent [136]. Microwave radiation provides a multiple acceleration of the reduction reaction due to heating of the reaction. The time of microwave exposure determines the type of crystal lattice of the synthesized Se nanoparticles [128,137]. In the method of gamma irradiation on the reduction of SeO₂ to Se⁰ [138], recovery occurs due to processes associated with water radiolysis [139]. In addition, it has been shown that gamma radiation can enhance the biogenic synthesis of SeNPs using fungi [140,141]. Principally, the microwave method and the use of gamma radiation can be attributed to the group of chemical reduction methods, but we singled them out separately, since they additionally need high-energy electromagnetic sources.

Laser ablation in a liquid belongs to the class of physical synthesis methods. It usually consists of obtaining nanoparticles using intense laser radiation from the surface of massive crystalline selenium targets immersed in a liquid. The laser ablation method has been described in detail [142]. During further laser irradiation of a colloid with nanoparticles, it is possible to obtain smaller NPs. This process is called fragmentation [143]. Physical evaporation is a method for synthesizing nanoparticles by treating a metal target with a laser in a vacuum, inert gas or atmospheric air. The method is essentially laser ablation carried out not in a solution, but in a gas and/or vacuum [144,145], so these methods were combined in this work.

In the case of the biological reduction method, biogenic synthesis and bioorganic synthesis are distinguished. In a significant number of works, the synthesis of SeNPs was carried out by biological reduction (“green synthesis”). This approach is also based on the reduction of selenium-containing precursors to Se⁰. The essential difference between the first and the second type is that biogenic synthesis uses cellular structures [115,131,146,147,148,149] and bioorganic synthesis uses noncellular extracts of plant and microbial origin to synthesize nanoparticles [117,132,150,151,152,153]. In this case, reducing agents are usually secondary metabolites, such as flavonoids, thiamine and capsaicin, as well as other agents containing amino groups, extracted from various plants: Spirulina platensis, Azadirachta indica, Trigonella foenum-graecum, Allium sativum, etc. [152,154,155,156,157]. The use of extracts during synthesis provides antibacterial, anticancer, or antioxidant properties of SeNPs [154,155,156,157]. SeNPs can be synthesized by cultivating microorganisms in a medium with an excess of SeNP precursors (sodium selenite (Na₂SeO₃) or SeO₂) [158]. For the synthesis of SeNPs, biomass and/or cell-free supernatants of bacterial cultures (Lactobacillus brevis, Lactobacillus casei, Bacillus licheniformis, Pseudomonas alcaliphila, etc.) [158,159,160,161,162], fungi (Aspergillus oryzae, Penicillium citrinum, Mariannaea sp.) [140,141,163] or yeasts (Saccharomyces cerevisiae, Magnusiomyces ingen) [164,165] can be used. Figure 4a shows the percentages of the various methods for the synthesis of selenium nanoparticles found in the literature.

2.1. Influence of the Method of Synthesis of Selenium Nanoparticles on the Resulting Size and Shape of Nanoparticles

Does the method of synthesis of nanoparticles affect their size? The results of our analysis are presented in Figure 4b. Obviously, physical methods of synthesis, such as laser ablation or microwave irradiation, make it possible to achieve a narrow size distribution of nanoparticles (Figure 4b). Most often, these are spherical particles less than 200 nm. Chemical or biological synthesis methods produce a wide range of particle sizes from 5 to 500 nm (Figure 4b). Within the framework of one type of synthesis, a preparation of nanoparticles with a wide size distribution of nanoparticles is usually obtained. At the same time, the vast majority of publications have synthesized spherical selenium nanoparticles. In some cases, other shapes, such as elongated cylinders [166], polygons [167] and granules [146], are observed.

2.2. Influence of Selenium Nanoparticle Synthesis Method on the Minimum Inhibitory Concentration in Antibacterial Studies

It has been established that the selenium nanoparticle synthesis method affects the value of the minimum inhibitory concentration in antibacterial studies (Table 1). The results of the analysis are shown in Figure 4c. It was noted that when using physical methods for the synthesis of selenium nanoparticles, the minimum inhibited concentration for effective antibacterial action did not exceed 100 µg/mL. When using microwave generation of nanoparticles, the MIC is approximately 100–300 µg/mL, which is significantly worse compared with nanoparticles obtained by other methods.

It should be noted that there are few studies that use nanoparticles synthesized using physical methods. Most likely, in the future, we should expect clarification of the data presented. For the methods of chemical and biological synthesis, the distribution of the obtained values of the minimum inhibited concentration is quite wide. In some cases, MICs of less than 1 µg/mL have been reported. At the same time, the average efficiency of nanoparticles obtained by both chemical and biological synthesis does not differ significantly. In general, the average efficiency of nanoparticles obtained by chemical/biological methods and using laser ablation does not differ significantly.

One of the ways to enhance the antibacterial and antifungal properties of SeNPs is their functionalization with enzymes and polymers during synthesis or inclusion in a polymer matrix. Examples of such components can be: arabinogalactan, propolis, lysozyme, bacterial cellulose, gelatin, reduced graphene oxide, chitosan, collagen and ε-poly-L-lysine [121,125,168,169,170,171,172,173]. The addition of SeNPs to textile fiber significantly enhances their antimicrobial properties [122,174]. The use of plant extracts (Urtica dioica, Ricinus communis, Artemisia annua, Nepeta sp., etc.) during synthesis also enhances the antibacterial and antifungal effects of SeNPs [117,148,150,175]. The addition of SeNPs to titanium oxide nanotubes enhances the antibacterial properties of the latter [176,177,178].

3. Effective Concentration/Minimum Inhibitory Concentration of Selenium Nanoparticles Depending on Their Size

3.1. Dependence of the Effective Concentration of Selenium Nanoparticles on Their Size for the Study of Antiviral Activity

We consider it necessary to start presenting the results with a study of antiviral activity. There are very few such research publications [120]. It seems that this is due to the increased complexity of organizing scientific work with viruses. Figure 5 shows the effective concentration of selenium nanoparticles depending on their size in the study of antiviral activity. The dependence is described with the equation y = 0.035·x + 1.08. By the nature of this dependence, it can be concluded that with a decrease in the size of nanoparticles, their effective concentration for antiviral action also decreases. This means that as the size of nanoparticles decreases, on average, they become more effective against viruses.

It should be noted that selenium nanoparticle synthesis, which is used in most antiviral studies, is a chemical reduction method. In the majority of research papers, spherical nanoparticles with a diameter of 10 to 200 nanometers were used. Published papers mainly use the H1N1 influenza virus (H1N1 influenza infecting Madin Darby canine kidney cell line) [179,180,181,182]. In addition, there are research publications investigating Enterovirus (Enterovirus 71—EV71) [183,184], hepatitis virus (HAV) [81,185,186], Cox-B4 virus (enteroviruses) [81], herpes virus (HSV-2 Herpes simplex II), influenza virus H1N1 [187] and adenovirus (Adenovirus strain 2) [187].

In the published research papers, two problems are investigated. The first task is to study the general antiviral action of selenium nanoparticles. The second task is to increase antiviral activity with the help of selenium nanoparticles in case of resistance of the virus to antiviral drugs. In other words, in the first task, researchers use “pure” selenium nanoparticles, and in the second task, selenium nanoparticles are processed (=functionalized) with the help of antiviral drug molecules. That is, selenium nanoparticles act as substrates for targeted delivery.

3.2. Dependence of the Minimum Inhibitory Concentration of Selenium Nanoparticles on Their Size and Shape in the Study of Antibacterial Activity

A large number of studies are published on this topic every year. For convenience, we present Table 2, which contains the analyzed publications of the antibacterial action of selenium nanoparticles. It should be noted that in most published research papers, three types of bacteria are used as objects: Bacillus subtilis, Staphylococcus aureus, and Escherichia coli. A box-and-whisker plot of the values of the minimum inhibitory concentration for these three types of bacteria is shown in Figure 6a.

Table 2. Dependence of the antimicrobial properties of SeNPs on the size, composition and method of synthesis.

№	Precursor	Composition	Method of the Synthesis	Particle Size, nm	Microorganism Strains	Effect	MIC	Results	Reference
1	Na2SeO3	Lysozyme SeNPs	Chemical reduction	35.6	Escherichia coli, Staphylococcus aureus	BS	82 μg/mL	SeNPs and lysozyme demonstrated synergetic bacteriostatic activity.	[121]
2	Na2SeO3	Propolis SeNPs	Bioorganic chemical reduction	159, 151.9, 11.2 and 169.3	Salmonella typhimurium ATCC 14028, Escherichia coli ATCC 25922, Staphylococcus aureus- ATCC 25923	BC	25 mg/L 27.5 mg/L 30 mg/L	BNCt/Pro/SeNPs were the most effective against all bacterial strains.	[168]
3	Na2SeO3	SeNPs	Chemical reduction	32.3	Staphylococcus aureus (MSSA), Staphylococcus aureus (MRSA), Staphylococcus aureus (VRSA), Enterococci (VRE)	BC; BS	20 µg/mL, 80 µg/mL, 320 µg/mL, and >320 µg/mL	SeNPs showed a synergistic effect with linezolid (LZD) through protein degradation against MSSA and MRSA.	[112]
4	Na2SeO3	SeNPs	Biosynthesis of SeNPs by Providencia sp.	120	P. aeruginosa, E. coli, V. parahemolyticus, S. aureus, B. cereus, B. subtilis	BC; BS	500 mg/L	Bio-SeNPs showed strong antibacterial effects on the five of pathogens at 100 mg/L. It was shown that most of G-bacteria (P. aeruginosa, E. coli and V. parahemolyticus) were locally killed by 500 mg/L of the bio-SeNPs after 12 h, which was better than G+-bacteria (S. aureus and B. cereus, except for B. subtilis).	[188]
5	Se (solid)	SeNPs	Pulsed laser ablation in liquids	~80 and ~10	E. coli (MDR-EC) ATCC BAA-2471, P. aeruginosa (PA) ATCC 27853, S. aureus (MRSA) ATCC 4330 Staphylococcus epidermidis ATCC 35984	BC; BS	25 µg/mL	SeNPs showed a dose-dependent antibacterial effect toward both standard and antibiotic-resistant phenotypes of Gram-negative and Gram-positive bacteria.	[113]
6	NaHSeO3	SeNPs with polyester fabrics	Chemical reduction	40–60	Salmonella typhi, Bacillus cereus, Escherichia coli, Pseudomonas aeruginosa	BC	1980 µg/mL	The treated fabric under study showed excellent killing potentiality against Gram-positive and Gram-negative bacteria.	[174]
7	NaHSeO3	Leather material/ SeNPs	Chemical reduction	36–77 and 41–149	Bacillus cereus, Pseudomonas aeruginosa, Salmonella typhi, Escherichia coli	BC	1980 µg/mL	Potential application to the footwear industry to color the leather as well as prevent the spread of bacterial infection promoted by humidity, poor breathability and temperature.	[122]
8	Na2SeO3	SeNPs/ orange peel waste extract	Bioorganic chemical reduction	16–95	Pseudomonas aeruginosa PAO1, MDR, S. aureus ATCC 29213	BS	25 µg/mL	The biosynthesized SeNPs had a promising antibiofilm activity, where the largest inhibition of biofilm was noticed in MDR K. pneumonia.	[169]
9	Na2SeO3	bacterial cellulose/ gelatin/ SeNPs hydrogels	Chemical reduction	75	E. coli, S. aureus	BC	65.44 μg	BC/Gel/SeNPs nanocomposite hydrogel: potential wound dressing for preventing wound infection and accelerating skin regeneration in clinic.	[189]
10	H2SeO3	rGO-S/Se composite	Chemical reduction	12	Staphylococcus aureus, Enterococcus faecalis	BS	200 µg/mL	Concentration and time-dependent BS activity of the rGO (Reduced graphene oxide)-S/Se NP against S. aureus cells	[170]
11	Na2SeO3	SeNPs	Biosynthesis of SeNPs by cyanobacteria Anabaena sp.	25	Staphylococcus aureus Escherichia coli	BS	50 µg/mL	These biogenic SeNPs demonstrated significant antibacterial and anti-biofilm activity against bacterial pathogens.	[131]
12	Na2SeO3	Ag-SeNPs	Biosynthesis of SeNPs by Aureobasidium pullulans	50 and 70	Staphylococcus aureus F1557 E. coli WT F1693	BC; BS	-	The Ag–Se coating reduced 81.2% and 59.7% of viable bacterial adhesion. The antibacterial mechanism of Ag–Se coatings works through effective contact-killing activity against S. aureus.	[146]
13	Na2SeO3	SeNP-chitosan, SeNPs-carboxymethyl cellulose	Chemical reduction	55–500 50–300	Staphylococcus aureus, methicillin-resistant Staphylococcus aureus, Staphylococcus epidermidis	BS	5 µg/mL	The SeNP-modified collagenous scaffolds at SeNP concentrations low as 5 µg/mL showed a strong antibacterial effect (up to 94% of bacterial growth inhibition) toward laboratory and clinical isolates of Gram-positive bacteria from the genus Staphylococcus.	[171]
14	Na2SeO3	SeNPs	Biosynthesis from Stenotrophomonas maltophilia SeI TE02	181	P. aeruginosa PAO1, INT, BR1 and BR2, S. maltophilia VR10 and VR20, Achromobacter xyloxidans strain C, Burkholderia cenocepacia strain LMG 16656, Staphylococcus aureus Mu50 strain, S. aureus UR1, Staphylococcus epidermidis ET024, Staphylococcus hemolitycus UST1	BS	4–128 μg/mL	The progressive loss in protein and carbohydrate content of the organic cap determines a decrease in nanoparticle stability. This leads to an alteration of size and electrical properties of SeNPs along with a gradual attenuation of their antibacterial efficacy.	[190]
15	Na2SeO4	SeNPs	Biosynthesis of SeNPs from Aspergillus quadrilineatus and Aspergillus ochraceus isolated from the twigs and leaves of Ricinus communis	45–75	Pseudomonas aeruginosa ATCC 15442, Bacillus cereus ATCC 10876, Staphylococcus aureus ATCC 6538, Klebsiella pneumoniae ATCC 13883, Bacillus subtilis TCC 6633, Escherichia coli ATCC 11229	BS	62.5–1000 µg/mL	SeNPs showed potent antifungal and antibacterial potentials against different human and phyto-pathogens.	[175]
16	Na2SeO3	“Green” SeNPs	Biosynthesis using aqueous leaf extract of U. dioica	10–87.4	Staphylococcus aureus ATCC 25923, Bacillus subtilis ATCC605, Escherichia coli ATCC 25922, Pseudomonas aeruginosa ATCC 27853 Fungi: Candida albicans, Cryptococcus neoformans	BS, FS	125, 62.5 and 15.62 µg/mL 3.9 and 7.81 µg/mL	SeNPs exhibited promising antibacterial activity against Gram-negative and Gram-positive bacteria and antifungal activity.	[150]
17	SeO2	SeNPs/tree gum	Chemical reduction	105.6	Bacillus subtilis, Micrococcus luteus	BS	12 μg/mL	The synthesized SeNPs inhibited the growth of the Gram-positive bacteria B. subtilis only.	[123]
18	Na2SeO3	SeNPs/chitosan	Chemical reduction	100	Staphylococcus aureus, Escherichia coli	BS	158 μg/mL	The antibacterial activity of CS(H)-SeNPs markedly decreased owing to the aggregation of NPs.	[166]
19	Na2SeO3	SeNPs	Phytofabrication of SeNPs from aqueous Spirulina platensis	79.4	Salmonella abony NCTC 6017, Klebsiella pneumonia ATCC 700603, E. coli ATCC 8739	BS	25–200 µg/mL	SeNPs have shown potent antimicrobial activity against Gram-negative bacteria. No toxic effect was observed for SeNPs on normal kidney and liver cell lines.	[191]
20	Na2SeO3	SeNPs	Biosynthesis of SeNPs from Nepeta plant powder	75	P. aeruginosa: ATCC 27853 and A. baumannii: ATCC BAA-747	BS	4 μg/mL 8 μg/mL	The inhibition of bacterial growth demonstrated in the presence of lower concentrations of SeNPs than common antibiotics.	[117]
21	Na2SeO3	Collagen/Chitosan/SeNPs	Chemical reduction	100–200	Staphylococcus aureus NCTC 8511, MRSA CCM 7110 and Escherichia coli NCTC 13216	BS	0.5–5 µg/mL	SeNPs are able to enhance the scaffold’s antibacterial properties toward S. aureus and MRSA at concentrations between 0.5 µg/mL and 5 µg/mL.	[172]
22	Na2SeO3	B-SeNPs	Biosynthesis of SeNPs from Anabaena variabilis (cyanobacteria)	10.8	Bacillus subtilis, Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae	BS	20 µg/mL	Cyanobacteria mediated synthesis can be considered as safe and nontoxic way to synthesize SeNPs.	[116]
23	Na2SeO3	SeNPs	Biosynthesis of SeNPs-S by Bacillus sp. Q33	159.2	E. coli, P. aeruginosa, S. aureus, L. monocytogenes	BS	200 µg/mL	SeNPs-S (product of whole cells) and SeNPs-E (product of the extracellular extract) exhibited obvious inhibitory effects on the four pathogenic bacteria.	[115]
24	Se (wafer)	SeNPs	Chemical reduction	42	E. coli, S. aureus	BS	0.2 mg/mL	The synergistic antibacterial effect of SeNPs and microstructured parylene-C.	[192]
25	H2Se	Arabinogalactan/ SeNPs	Bioorganic synthesis with AG from Larix Sibirica isolated	94	bacterial phytopathogen Clavibacter michiganensis sepedonicus (Cms)	BS	6.25 μg/mL	Antimicrobial activity of AG/SeNPs is due to their ability to inhibit the dehydrogenase activity of Cms cells, to disrupt the integrity of the cell membrane, resulting in a decrease of transmembrane potential and reduction of cellular respiration.	[125]
26	Na2SeO3	Cefotaxime/Ag–SeNPs	Gamma irradiation	34.5; 24.9	E. coli, P. aeruginosa, K. pneumoniae, S. aureus, Enterococcus sp.	BS; BC	2.5–5 μg/mL; 0.625–2.5 μg/mL (with CFM)	Ag NPs-CFM, SeNPs-CFM and Ag–SeNPs-CFM possessed antimicrobial activity against Staphylococcus aureus, Escherichia coli.	[193]
27	Na2SeO3s	SeNPs	Chemical reduction	70	Porphyromonas gingivalis	BS; BC	4–16 μg/mL	The growth of P. gingivalis was significantly inhibited by SeNPs.	[114]
28	SeO2	Se NP-ε-poly-L-lysine	chemical reduction	82	S. aureus ATCC 29213, S. aureus (MRSA) ATCC 43300, E. faecalis ATCC 29212, E. coli ATCC 25922, A. baumannii 2208, ATCC 19606, P. aeruginosa strain PAO1-LAC ATCC 47085, K. pneumoniae ATCC 13883, and K. pneumoniae (MDR) FADDI-KP628	BS; BC	6−26 μg/mL	The MICs of Se NP-ε-PL against the eight different types of bacteria tested are approximately 6–26 μg/mL.	[173]
29	Na2SeO3	SeNPs	Biosynthesis by Se-resistant Bacillus subtilis AS12	77	Aeromonas hydrophilia Staphylococcus aureus, Bacillus cereus, Listeria monocytogenes, Escherichia coli, Aeromonas hydrophilia, Klebsiella pneumonia	BS; BC	3–5 μg/mL	Bio-SeNPs can mitigate the accumulation of heavy metals and reduce the bacterial load in a concentration-dependent manner.	[194]
30	Na2SeO3	TiO2 nanotube with SeNPs	chemical reduction	88.93	E. coli	BS	-	Selenium nanoparticles improved antibacterial properties of titanium dioxide nanotubes.	[176]
31	Na2SeO3	SeNPs	microwave technique in the presence of citric acid	10.5–20	P. aeruginosa, E. coli, B. subtilis, S. aureus	BS	100 mg/mL	SeNPs had the highest activity against E. coli, with a zone of inhibition (ZOI) of 25.2 ± 1.5 mm compared to 16.0 ± 0.6 mm for the standard antibiotic.	[136]
32	Na2SeO3	SeNPs	biosynthesis of SeNPs by endophytic fungal strain Penicillium crustosum EP-1	3–22	Bacillus subtilis ATCC 6633, Staphylococcus aureus ATCC 6538, Escherichia coli ATCC 8739, Pseudomonas aeruginosa ATCC 9022	BS	12.5 µg/mL 50 µg/mL 50 µg/mL 25 µg/mL (in the presence of light) 50 µg/mL, 100 µg/mL (under dark conditions)	The effect of SeNPs was dose-dependent, and higher activities against bacteria were attained in the presence of light than were attained under dark conditions.	[147]
33	Na2SeO3	Mk-SeNPs	chemical reduction with the presence of aqueous berry extract of Murraya koenigii (Mk-SeNPs)	50–150	Streptococcus mutans (HQ 693279.1 & ATCC 25175), Enterococcus faecalis Shigella sonnei, Pseudomonas aeruginosa (K 7769531 & HQ 693272	BS; BC	40 μg/mL 50 μg/mL	Mk-SeNPs are considered to be a prospective antibacterial agent with effective antioxidant capacity at 25 and 50 μg/mL, which is target-specific only for the bacterial cells and not for the erythrocytes and macrophages at the same concentration.	[195]
34	Na2SeO3	SeNPs	The abiotic reduction of selenite with the use of Enterococcus spp. cell-free extract (biotic and abiotic stages)	200	E. coli	BS	3.2 g/L	The obtained nanoparticles exhibited antimicrobial properties by directly inhibiting the viability of an E. coli bacterial strain. The results demonstrate not only the potential of abiotic production of SeNPs but also the potential for these particles as microbial inhibitors in medical or similar fields.	[196]
35	Na2SeO3	SeNPs	chemical reduction with PVA as a stabilizer	30–70	S. aureus (ATCC 29213), E. coli (ATCC 25922)	BS	1 μg/mL	The growth of S. aureus was inhibited by the nanoparticles at concentrations as low as 1 μg/mL.	[197]
36	Na2SeO3	Artemisia annua extract/SeNPs	Biosynthesized using Artemisia annua, and subsequently, the surface of the biogenic SeNPs was functionally modified with starch.	<200	Staphylococcus aureus, Bacillus cereus, Salmonella enterica, Escherichia coli	BS; BC	5–100 μg/mL	StAaSeNPs showed the highest antibacterial activity against tested strains S. enterica (23.26 ± 0.35 mm). Based on the findings, it can be inferred that surface chemistry is the most influential factor in determining the antibacterial activity of SeNPs.	[148]
37	Na2SeO3	Hollow SeNPs	Bioorganic synthesis of SeNPs with the potato extract	115	B. subtilis (MTCC441), E. coli (MTCC40)	BC	10–20 μg/mL	The hSeNPs showed good antibacterial activity against tested bacteria.	[198]
38	SeO2	SeNPs	chemical reduction with the presence of PVA	43–205	Staphylococcus aureus (MSSA) ATCC 29213, Staphylococcus aureus (MRSA) ATCC 43300	BC	16 µg/mL	The SeNPs were shown to have multimodal mechanisms of action that depended on their size, including depleting internal ATP, inducing ROS production, and disrupting membrane potential.	[199]
39	Na2SeO3	BSA/ SeNPs	chemical reduction method in the presence of the BSA	20–30	Escherichia coli (ATCC no. 25922), Escherichia coli (ATCC no. BAA-2471), Staphylococcus aureus (ATCC no. 25923)	BC	1 mg/mL	SeNPs achieved a 10-fold reduction for S. aureus.	[200]
40	SeO2	eADF4(κ16)/SeNPs PVA/ SeNPs	chemical reduction method in the presence of the spider silk protein eADF4(κ16) and PVA (Polyvinyl alcohol)	46	Escherichia coli	BC	8 ± 1 µg/mL 405 ± 80 µg/mL	The eADF4(κ16)-coated SeNPs demonstrated a much higher bactericidal efficacy against the E. coli, with a minimum bactericidal concentration (MBC) approximately 50 times lower than that of PVA/SeNPs.	[201]
41	Na2SeO3	mycogenic SeNPs SeNPs-CN	2 methods: a biogenic process using Penicillium chrysogenum filtrate and by utilizing gentamicin drug (CN) following the application of gamma irradiation	33.84 22.37	Staphylococcus aureus, Bacillus subtilis, Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae Fungi: Candida albicans	BC, FC	0.490 μg/mL 0.245 μg/mL	The synthesized SeNPs-CN possesses an encouraging antimicrobial potential with respect to the biogenic SeNPs against all examined microbes. Remarkably, SeNPs-CN showed antimicrobial potential toward 23.0 mm ZOI for Escherichia coli and 20.0 mm ZOI against Staphylococcus aureus. It also inhibited the expansion and invasion of C. albicans suggested the use of gentamycin as antifungal agent after the combination with the synthesized SeNPs.	[202]
42	Se (pellets)	SeNPs	Pulsed laser ablation in liquids	115	Escherichia coli, Staphylococcus aureus	BC	50 µg/mL	The pure selenium nanoparticles determined the minimal concentration required for ~50% inhibition of either E. coli or S. aureus after 24 h to be at least ~50 µg/mL.	[203]
43	H2SeO3	Green Orange Peel extract/SeNPs	Chemical reduction in the presence of BSA—stabilizer	18.3	S. aureus (ATCC 25923), S. epidermidis (ATCC 1228)	BS	4.94 μg/L	The SeNP sample demonstrated excellent antibacterial activity with an average diameter of inhibition zones of 20.0 mm and an MIC of 4.94 μg/L.	[124]
44	Na2SeO3	SeNPs	Bioorganic synthesis of SeNPs with the use of Penicillium corylophilum As-1 biomass filtrate, in presence of ascorbic acid as a reducing agent	29.1–48.9	Staphylococcus aureus ATCC 6538, Bacillus subtilis ATCC 6633, Escherichia coli ATCC 8739, Pseudomonas aeruginosa ATCC 9027	BS	9.37 μg/mL 18.75 μg/mL 37.5 μg/mL 37.5 μg/mL	The formed SeNPs showed a prominent antimicrobial activity at different concentrations against the pathogens Staphylococcus aureus, Bacillus subtilis, Pseudomonas aeruginosa and E. coli.	[132]
45	SeO2	Penicillium expansum/SeNPs	biosynthesis with Penicillium expansum ATTC 36200	4–12.7	Bacillus subtilis ATCC 6051, Staphylococcus aureus ATCC 23235, Escherichia coli ATCC 8739, Pseudomonas aeruginosa ATCC 9027 Fungi: Candida albicans ATCC 90028, Aspergillus fumigatus RCMB 02568, A. niger RCMB 02724	BS, FS	62.5 μg/mL 62.5 μg/mL 125 μg/mL 125 μg/mL 125 μg/mL 125 μg/mL 125 μg/mL	The inhibitory effect against Gram-positive bacteria was more pronounced than against Gram-negative bacteria and fungi.	[149]
46	Na2SeO3	Chitosan/SeNPs	chemical reduction	77	Streptococcus mutans	BS	128 and 64 µg/mL	The comparison between the treated and untreated groups showed that combining therapy with SeNPs and PDT markedly decreased colony-forming units of one-day-old S. mutans biofilm.	[204]
47	SeO2	SeNPs	solvothermal method using Moringa oleifera leaf extract as a reducing agent	82.86	Listeria innocua ATCC 33090, Bacillus cereus ATCC 10876, Escherichia coli ATCC 43888, Salmonella typhimurium ATCC 14028	BS	100 μg/mL	Zones of inhibition were observed only in S. typhimurium (12.5 ± 0.5 mm), E. coli (10.1 ± 0.7 mm) and B. cereus (9.8 ± 0.7 mm).	[167]
48	Na2SeO3	SeNPs	green synthesis using ascorbic acid as a reducing agent and methanolic extract of Calendula officinalis L. flowers as a stabilizer	40–60	Serratia marcescens, Enterobacter cloacae, Alcaligenes faecalis	BS	-	The antibacterial activity of the extract, AsAc, and Na2SeO3 was enhanced by producing the SeNPs, which significantly inhibited the growth of S. marcescens, E. cloacae, and A. faecalis bacterial strains.	[205]
49	Na2SeO3	SeNPs	Chemical reduction synthesis from extracts of three plants: Allium cepa (onion), Malpighia emarginata (acerola), and Gymnanthemum amygdalinum (boldo)	245–321	Streptococcus agalactiae, Staphylococcus aureus, S. aureus, Pseudomonas aeruginosa, Escherichia coli	BS	6.125 to 98 μg/mL	The antimicrobial activity and low hemolytic concentration indicate the possibility of use against Gram-positive bacteria, including multidrug-resistant ones, opening a wide variety of options for their application	[151]
50	SeO2	Algae/ SeNPs	Microwave-assisted synthesis of SeNPs	40	V. harveyi (PTCC 1755)	BS	200 μg/mL	The presence of different functional groups of Sargassum angustifolium on the surface of the algae-coated SeNPs might be responsible for the more effective reaction of these nanoparticles with the cell walls and/or membrane of V. harveyi.	[206]
51	Na2SeO3	SeNPs	chemical reduction	71	V. cholerae O1 ATCC 14035 strain	BS	50–200 μg/mL	SeNPs are safe as an antibacterial and antibiofilm agent against V. cholerae O1 ATCC 14035 strain.	[207]
52	Na2SeO3	SeNPs, NCT/GA, NCT/GA/Eug and NCT/GA/Eug/SeNPs	chemical reduction	9.7, 124.8, 132.6 and 134.2 nm	Escherichia coli, Staphylococcus aureus	BS; BC	15.0 μg/mL 20 μg/mL	The entire fabricated nanocomposite exhibited potent antibacterial activity and cell destruction capability within 5–10 h of exposure.	[208]
53	Na2SeO3	SeNPs	synthesis and purification, in the presence of pepper extract; chemical reduction method, plus microwave	79–90 nm	Escherichia coli ATCC BAA-2471, Staphylococcus aureus ATCC 4330	BS	72,2 μg/mL 85,1 μg/mL	Selenium nanoparticles were biocompatible and showed bacteriostatic activity	[152]
54	Na2SeO3	SeNPs	biosynthesized with a standard strain of C. albicans	38	Fungi: Candida albicans, Candida glabrata	FS	1 and 0.5 µg/mL	SeNPs showed much better fungistatic activity compared to itraconazole, amphotericin B and anidulafungin.	[209]
55	Na2SeO3	SeNPs	Biosynthesis from lactic acid bacteria (LAB)	56	Fungi: Candida and Fusarium species	FC	80–130 µg/mL	The LAB-SeNPs MFC was in the range of 80–130 µg/mL, which ensured the complete killing of all tested fungi.	[210]
56	Na2SeO4	SeNPs	Biosynthesis with standard strains of A. Flavus and C. albicans	37 and 38	Fungi: Candida and Aspergillus species	FS	0.5, and 0.25 μg/mL	The utilization of SeNPs at concentrations of 1, 0.5 and 0.25 μg/mL or in, some strains, even lesss than 0.125 μg/mL, resulted in zero growth of fungal agents.	[126]
57	Na2SeO3	SeNPs	“green” method using the Halomonas elongata bacterium	11	Fungi: Candida albicans	FS	-	The synthesized NPs in optimal situation stopped the growth of Candida albicans up to 72%.	[211]
58	Se (pellets)	Chitosan/SeNPs	laser ablation in liquids	100	Fungi: C. albicans TW17 and 6486 strains	FC, FS	3.5 μg/mL	Taken separately, SeNPs and CS have shown fungicidal properties, but when combined (CS-SeNPs), achieved a potent inhibitory effect against the mature biofilm in a dose–response manner.	[212]
59	Na2SeO3	SeNPs	biosynthesis with the leaf extract of Melia azedarach	74	Fungi: Fusarium mangiferae	FC	300 μg/mL	Biogenic selenium NPs are widely expected to be efficient and cost-effective treatments for fungal plant diseases.	[213]
60	Na2SeO3	SeNPs	green synthesis using extracts from A. glaucum leaves and C. officinalis flowers	8 and 133	Fungi: Fusarium oxysporum, Colletotrichum gloeosporioides	FS	0.25 mg/mL	It was observed that both SeNPs had antifungal activity against both plant pathogens at concentrations of 0.25 mg/mL and above. SeNPs-AGL demonstrated better antifungal activity and smaller size (approximately 8.0 nm) than SeNPs-COF (134.0 nm).	[214]
61	Na2SeO3	SeNPs	biosynthesis by Lactobacillus aci- dophilus ML1	46	Fungi: Fusarium culmorum, Fusarium graminearum	FC	100 mg/mL	Under greenhouse conditions, the wheat supplemented with BioSeNPs (100 mg/mL) experienced significantly incidence of crown and root rot diseases by 75% and considerably enhanced plant growth, grain quantity and quality by 5–40%.	[215]
62	SeCl4	SeNPs	biosynthesis using endophytic fungus Fusarium oxysporum	42	Fungi: Aspergillus niger	FS	8 mg/mL; diluted to 4, 2, 1, 0.5, and 0.25 mg/mL	SeNPs showed excellent antifungal and antisporulant activity against black fungus Aspergillus niger, which has become life-threatening to SARS-CoV-2 patients during the pandemic.	[127]
63	Na2SeO4	SeNPs	biosynthesis with the use of Aspergillus strains	64.8	Fungi: Aspergillus fumigatus, Aspergillus flavus	FS	0.5 µg/mL	The MIC of itraconazole and amphotericin B against A. fumigatus and A. flavus was 4 μg/mL, whereas the MIC values for treated samples with SeNPs have decreased to 0.5 μg/mL.	[216]
64	Na2SeO3	SeNPs	biosynthesis using the extract of Melia azedarach leaves	61	Fungi: Puccinia striformis	FS	30 mg/L	SeNPs at a concentration of 30 mg/L reduced the disease severity and enhanced the morphological, physiological, biochemical and antioxidant parameters.	[217]
65	Na2SeO3	PPE/SeNPs and NCT/PPE/SeNPs	Pomegranate peel extract (PPE) used for biosynthesis	9.4 85	Fungi: Penicillium digitatum	FC	22.5 15 mg/mL	NCT/PPE/SeNPs nanocomposite was the most effective and significantly exceeded the fungicidal action of standard fungicide. The direct treatment of fungal mycelia with NCT/PPE/SeNPs nanocomposite led to remarkable lysis and deformations of P. digitatum hyphae within 12 h of treatment.	[218]
66	H2SeO3	SeNPs	Biosynthesis by Bacillus megaterium ATCC 55000	41.2	Fungi: Rhizoctonia solani RCMB 031001	FS, FC	0.0625 and 1 mM	SeNPs improve morphological and metabolic indicators and yield significantly compared with infected control.	[219]
67	Na2SeO3	SeNPs	chemical reduction method with the use of the Trichoderma atroviride cell culture lysate	93.2–98.5	Fungi: Pyricularia grisea, Colletotrichum capsici, Alternaria solani on chili and tomato leaves	FS	50 μg/mL 100 μg/mL 100 μg/mL	The synthesized nanoparticles displayed excellent in vitro antifungal activity against Pyricularia grisea and inhibited the infection of Colletotrichum capsici and Alternaria solani on chili and tomato leaves.	[220]
68	Na2SeO3	bovine serum albumin (BSA)/ SeNP, ascorbic acid/)/ SeNP, chitosan/SeNP, glucose/SeNP	chemical reduction method	70–300	Staphylococcus aureus (ATCC 6538), Enterococcus faecalis (ATCC 29212), Bacillus subtilis (ATCC 6633), and Kocuria rhizophila (ATCC 9341), Escherichia coli (ATCC 8739), Salmonella sp. (NCTC 6017), Klebsiella pneumoniae (NCIMB 9111), Pseudomonas aeruginosa (ATCC 9027), Fungi: Candida albicans (ATCC 10231)	BS, BC, FC	100 μg/mL 100 μg/mL 200 μg/mL 200 μg/mL 400 μg/mL 400 μg/mL 200 μg/mL 400 μg/mL 25 μg/mL	Chitosan/SeNPs had greater antibacterial and antifungal activity than BSA/SeNPs and glucose/SeNPs. The MIC for Gram-positive bacteria was higher.	[221]
69	Na2SeO3	TiO2-nanotubes/ SeNPs, AgNPs or Ag2SeNP	electrolysis of Na2SO3	<10	Staphylococcus epidermidis	BS	-	Nanocomposite reduced bacterial growth and biofilm formation. In comparison with the non-modifed control, the TiO2-nanotubes/SeNPs surfaces showed a signifcantly higher coverage area with osteoblastic MG-63-cells.	[177]
70	Na2SeO3	TiO2-nanotubes/ SeNPs	Chemical reduction in presence of TiO2-nanotubes	<10	Escherichia coli, Staphylococcus aureus	BS	-	Samples reduced the density of E. coli by 94.6% and of S. aureus by 89.6% compared to titanium controls.	[178]
71	Na2SeO3	polycarbonate films/SeNPs	Chemical reduction by glutation	50–100	Staphylococcus aureus	BS		Polycarbonate films/SeNPs inhibited bacterial growth to 8.9% and 27% when compared with an uncoated polycarbonate surface after 24 and 72 h, respectively.

BC—bactericidal effect, BS—bacteriostatic effect, FC—fungicidal effect, FS—fungistatic effect.

Table 2. Dependence of the antimicrobial properties of SeNPs on the size, composition and method of synthesis.

№	Precursor	Composition	Method of the Synthesis	Particle Size, nm	Microorganism Strains	Effect	MIC	Results	Reference
1	Na2SeO3	Lysozyme SeNPs	Chemical reduction	35.6	Escherichia coli, Staphylococcus aureus	BS	82 μg/mL	SeNPs and lysozyme demonstrated synergetic bacteriostatic activity.	[121]
2	Na2SeO3	Propolis SeNPs	Bioorganic chemical reduction	159, 151.9, 11.2 and 169.3	Salmonella typhimurium ATCC 14028, Escherichia coli ATCC 25922, Staphylococcus aureus- ATCC 25923	BC	25 mg/L 27.5 mg/L 30 mg/L	BNCt/Pro/SeNPs were the most effective against all bacterial strains.	[168]
3	Na2SeO3	SeNPs	Chemical reduction	32.3	Staphylococcus aureus (MSSA), Staphylococcus aureus (MRSA), Staphylococcus aureus (VRSA), Enterococci (VRE)	BC; BS	20 µg/mL, 80 µg/mL, 320 µg/mL, and >320 µg/mL	SeNPs showed a synergistic effect with linezolid (LZD) through protein degradation against MSSA and MRSA.	[112]
4	Na2SeO3	SeNPs	Biosynthesis of SeNPs by Providencia sp.	120	P. aeruginosa, E. coli, V. parahemolyticus, S. aureus, B. cereus, B. subtilis	BC; BS	500 mg/L	Bio-SeNPs showed strong antibacterial effects on the five of pathogens at 100 mg/L. It was shown that most of G-bacteria (P. aeruginosa, E. coli and V. parahemolyticus) were locally killed by 500 mg/L of the bio-SeNPs after 12 h, which was better than G+-bacteria (S. aureus and B. cereus, except for B. subtilis).	[188]
5	Se (solid)	SeNPs	Pulsed laser ablation in liquids	~80 and ~10	E. coli (MDR-EC) ATCC BAA-2471, P. aeruginosa (PA) ATCC 27853, S. aureus (MRSA) ATCC 4330 Staphylococcus epidermidis ATCC 35984	BC; BS	25 µg/mL	SeNPs showed a dose-dependent antibacterial effect toward both standard and antibiotic-resistant phenotypes of Gram-negative and Gram-positive bacteria.	[113]
6	NaHSeO3	SeNPs with polyester fabrics	Chemical reduction	40–60	Salmonella typhi, Bacillus cereus, Escherichia coli, Pseudomonas aeruginosa	BC	1980 µg/mL	The treated fabric under study showed excellent killing potentiality against Gram-positive and Gram-negative bacteria.	[174]
7	NaHSeO3	Leather material/ SeNPs	Chemical reduction	36–77 and 41–149	Bacillus cereus, Pseudomonas aeruginosa, Salmonella typhi, Escherichia coli	BC	1980 µg/mL	Potential application to the footwear industry to color the leather as well as prevent the spread of bacterial infection promoted by humidity, poor breathability and temperature.	[122]
8	Na2SeO3	SeNPs/ orange peel waste extract	Bioorganic chemical reduction	16–95	Pseudomonas aeruginosa PAO1, MDR, S. aureus ATCC 29213	BS	25 µg/mL	The biosynthesized SeNPs had a promising antibiofilm activity, where the largest inhibition of biofilm was noticed in MDR K. pneumonia.	[169]
9	Na2SeO3	bacterial cellulose/ gelatin/ SeNPs hydrogels	Chemical reduction	75	E. coli, S. aureus	BC	65.44 μg	BC/Gel/SeNPs nanocomposite hydrogel: potential wound dressing for preventing wound infection and accelerating skin regeneration in clinic.	[189]
10	H2SeO3	rGO-S/Se composite	Chemical reduction	12	Staphylococcus aureus, Enterococcus faecalis	BS	200 µg/mL	Concentration and time-dependent BS activity of the rGO (Reduced graphene oxide)-S/Se NP against S. aureus cells	[170]
11	Na2SeO3	SeNPs	Biosynthesis of SeNPs by cyanobacteria Anabaena sp.	25	Staphylococcus aureus Escherichia coli	BS	50 µg/mL	These biogenic SeNPs demonstrated significant antibacterial and anti-biofilm activity against bacterial pathogens.	[131]
12	Na2SeO3	Ag-SeNPs	Biosynthesis of SeNPs by Aureobasidium pullulans	50 and 70	Staphylococcus aureus F1557 E. coli WT F1693	BC; BS	-	The Ag–Se coating reduced 81.2% and 59.7% of viable bacterial adhesion. The antibacterial mechanism of Ag–Se coatings works through effective contact-killing activity against S. aureus.	[146]
13	Na2SeO3	SeNP-chitosan, SeNPs-carboxymethyl cellulose	Chemical reduction	55–500 50–300	Staphylococcus aureus, methicillin-resistant Staphylococcus aureus, Staphylococcus epidermidis	BS	5 µg/mL	The SeNP-modified collagenous scaffolds at SeNP concentrations low as 5 µg/mL showed a strong antibacterial effect (up to 94% of bacterial growth inhibition) toward laboratory and clinical isolates of Gram-positive bacteria from the genus Staphylococcus.	[171]
14	Na2SeO3	SeNPs	Biosynthesis from Stenotrophomonas maltophilia SeI TE02	181	P. aeruginosa PAO1, INT, BR1 and BR2, S. maltophilia VR10 and VR20, Achromobacter xyloxidans strain C, Burkholderia cenocepacia strain LMG 16656, Staphylococcus aureus Mu50 strain, S. aureus UR1, Staphylococcus epidermidis ET024, Staphylococcus hemolitycus UST1	BS	4–128 μg/mL	The progressive loss in protein and carbohydrate content of the organic cap determines a decrease in nanoparticle stability. This leads to an alteration of size and electrical properties of SeNPs along with a gradual attenuation of their antibacterial efficacy.	[190]
15	Na2SeO4	SeNPs	Biosynthesis of SeNPs from Aspergillus quadrilineatus and Aspergillus ochraceus isolated from the twigs and leaves of Ricinus communis	45–75	Pseudomonas aeruginosa ATCC 15442, Bacillus cereus ATCC 10876, Staphylococcus aureus ATCC 6538, Klebsiella pneumoniae ATCC 13883, Bacillus subtilis TCC 6633, Escherichia coli ATCC 11229	BS	62.5–1000 µg/mL	SeNPs showed potent antifungal and antibacterial potentials against different human and phyto-pathogens.	[175]
16	Na2SeO3	“Green” SeNPs	Biosynthesis using aqueous leaf extract of U. dioica	10–87.4	Staphylococcus aureus ATCC 25923, Bacillus subtilis ATCC605, Escherichia coli ATCC 25922, Pseudomonas aeruginosa ATCC 27853 Fungi: Candida albicans, Cryptococcus neoformans	BS, FS	125, 62.5 and 15.62 µg/mL 3.9 and 7.81 µg/mL	SeNPs exhibited promising antibacterial activity against Gram-negative and Gram-positive bacteria and antifungal activity.	[150]
17	SeO2	SeNPs/tree gum	Chemical reduction	105.6	Bacillus subtilis, Micrococcus luteus	BS	12 μg/mL	The synthesized SeNPs inhibited the growth of the Gram-positive bacteria B. subtilis only.	[123]
18	Na2SeO3	SeNPs/chitosan	Chemical reduction	100	Staphylococcus aureus, Escherichia coli	BS	158 μg/mL	The antibacterial activity of CS(H)-SeNPs markedly decreased owing to the aggregation of NPs.	[166]
19	Na2SeO3	SeNPs	Phytofabrication of SeNPs from aqueous Spirulina platensis	79.4	Salmonella abony NCTC 6017, Klebsiella pneumonia ATCC 700603, E. coli ATCC 8739	BS	25–200 µg/mL	SeNPs have shown potent antimicrobial activity against Gram-negative bacteria. No toxic effect was observed for SeNPs on normal kidney and liver cell lines.	[191]
20	Na2SeO3	SeNPs	Biosynthesis of SeNPs from Nepeta plant powder	75	P. aeruginosa: ATCC 27853 and A. baumannii: ATCC BAA-747	BS	4 μg/mL 8 μg/mL	The inhibition of bacterial growth demonstrated in the presence of lower concentrations of SeNPs than common antibiotics.	[117]
21	Na2SeO3	Collagen/Chitosan/SeNPs	Chemical reduction	100–200	Staphylococcus aureus NCTC 8511, MRSA CCM 7110 and Escherichia coli NCTC 13216	BS	0.5–5 µg/mL	SeNPs are able to enhance the scaffold’s antibacterial properties toward S. aureus and MRSA at concentrations between 0.5 µg/mL and 5 µg/mL.	[172]
22	Na2SeO3	B-SeNPs	Biosynthesis of SeNPs from Anabaena variabilis (cyanobacteria)	10.8	Bacillus subtilis, Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae	BS	20 µg/mL	Cyanobacteria mediated synthesis can be considered as safe and nontoxic way to synthesize SeNPs.	[116]
23	Na2SeO3	SeNPs	Biosynthesis of SeNPs-S by Bacillus sp. Q33	159.2	E. coli, P. aeruginosa, S. aureus, L. monocytogenes	BS	200 µg/mL	SeNPs-S (product of whole cells) and SeNPs-E (product of the extracellular extract) exhibited obvious inhibitory effects on the four pathogenic bacteria.	[115]
24	Se (wafer)	SeNPs	Chemical reduction	42	E. coli, S. aureus	BS	0.2 mg/mL	The synergistic antibacterial effect of SeNPs and microstructured parylene-C.	[192]
25	H2Se	Arabinogalactan/ SeNPs	Bioorganic synthesis with AG from Larix Sibirica isolated	94	bacterial phytopathogen Clavibacter michiganensis sepedonicus (Cms)	BS	6.25 μg/mL	Antimicrobial activity of AG/SeNPs is due to their ability to inhibit the dehydrogenase activity of Cms cells, to disrupt the integrity of the cell membrane, resulting in a decrease of transmembrane potential and reduction of cellular respiration.	[125]
26	Na2SeO3	Cefotaxime/Ag–SeNPs	Gamma irradiation	34.5; 24.9	E. coli, P. aeruginosa, K. pneumoniae, S. aureus, Enterococcus sp.	BS; BC	2.5–5 μg/mL; 0.625–2.5 μg/mL (with CFM)	Ag NPs-CFM, SeNPs-CFM and Ag–SeNPs-CFM possessed antimicrobial activity against Staphylococcus aureus, Escherichia coli.	[193]
27	Na2SeO3s	SeNPs	Chemical reduction	70	Porphyromonas gingivalis	BS; BC	4–16 μg/mL	The growth of P. gingivalis was significantly inhibited by SeNPs.	[114]
28	SeO2	Se NP-ε-poly-L-lysine	chemical reduction	82	S. aureus ATCC 29213, S. aureus (MRSA) ATCC 43300, E. faecalis ATCC 29212, E. coli ATCC 25922, A. baumannii 2208, ATCC 19606, P. aeruginosa strain PAO1-LAC ATCC 47085, K. pneumoniae ATCC 13883, and K. pneumoniae (MDR) FADDI-KP628	BS; BC	6−26 μg/mL	The MICs of Se NP-ε-PL against the eight different types of bacteria tested are approximately 6–26 μg/mL.	[173]
29	Na2SeO3	SeNPs	Biosynthesis by Se-resistant Bacillus subtilis AS12	77	Aeromonas hydrophilia Staphylococcus aureus, Bacillus cereus, Listeria monocytogenes, Escherichia coli, Aeromonas hydrophilia, Klebsiella pneumonia	BS; BC	3–5 μg/mL	Bio-SeNPs can mitigate the accumulation of heavy metals and reduce the bacterial load in a concentration-dependent manner.	[194]
30	Na2SeO3	TiO2 nanotube with SeNPs	chemical reduction	88.93	E. coli	BS	-	Selenium nanoparticles improved antibacterial properties of titanium dioxide nanotubes.	[176]
31	Na2SeO3	SeNPs	microwave technique in the presence of citric acid	10.5–20	P. aeruginosa, E. coli, B. subtilis, S. aureus	BS	100 mg/mL	SeNPs had the highest activity against E. coli, with a zone of inhibition (ZOI) of 25.2 ± 1.5 mm compared to 16.0 ± 0.6 mm for the standard antibiotic.	[136]
32	Na2SeO3	SeNPs	biosynthesis of SeNPs by endophytic fungal strain Penicillium crustosum EP-1	3–22	Bacillus subtilis ATCC 6633, Staphylococcus aureus ATCC 6538, Escherichia coli ATCC 8739, Pseudomonas aeruginosa ATCC 9022	BS	12.5 µg/mL 50 µg/mL 50 µg/mL 25 µg/mL (in the presence of light) 50 µg/mL, 100 µg/mL (under dark conditions)	The effect of SeNPs was dose-dependent, and higher activities against bacteria were attained in the presence of light than were attained under dark conditions.	[147]
33	Na2SeO3	Mk-SeNPs	chemical reduction with the presence of aqueous berry extract of Murraya koenigii (Mk-SeNPs)	50–150	Streptococcus mutans (HQ 693279.1 & ATCC 25175), Enterococcus faecalis Shigella sonnei, Pseudomonas aeruginosa (K 7769531 & HQ 693272	BS; BC	40 μg/mL 50 μg/mL	Mk-SeNPs are considered to be a prospective antibacterial agent with effective antioxidant capacity at 25 and 50 μg/mL, which is target-specific only for the bacterial cells and not for the erythrocytes and macrophages at the same concentration.	[195]
34	Na2SeO3	SeNPs	The abiotic reduction of selenite with the use of Enterococcus spp. cell-free extract (biotic and abiotic stages)	200	E. coli	BS	3.2 g/L	The obtained nanoparticles exhibited antimicrobial properties by directly inhibiting the viability of an E. coli bacterial strain. The results demonstrate not only the potential of abiotic production of SeNPs but also the potential for these particles as microbial inhibitors in medical or similar fields.	[196]
35	Na2SeO3	SeNPs	chemical reduction with PVA as a stabilizer	30–70	S. aureus (ATCC 29213), E. coli (ATCC 25922)	BS	1 μg/mL	The growth of S. aureus was inhibited by the nanoparticles at concentrations as low as 1 μg/mL.	[197]
36	Na2SeO3	Artemisia annua extract/SeNPs	Biosynthesized using Artemisia annua, and subsequently, the surface of the biogenic SeNPs was functionally modified with starch.	<200	Staphylococcus aureus, Bacillus cereus, Salmonella enterica, Escherichia coli	BS; BC	5–100 μg/mL	StAaSeNPs showed the highest antibacterial activity against tested strains S. enterica (23.26 ± 0.35 mm). Based on the findings, it can be inferred that surface chemistry is the most influential factor in determining the antibacterial activity of SeNPs.	[148]
37	Na2SeO3	Hollow SeNPs	Bioorganic synthesis of SeNPs with the potato extract	115	B. subtilis (MTCC441), E. coli (MTCC40)	BC	10–20 μg/mL	The hSeNPs showed good antibacterial activity against tested bacteria.	[198]
38	SeO2	SeNPs	chemical reduction with the presence of PVA	43–205	Staphylococcus aureus (MSSA) ATCC 29213, Staphylococcus aureus (MRSA) ATCC 43300	BC	16 µg/mL	The SeNPs were shown to have multimodal mechanisms of action that depended on their size, including depleting internal ATP, inducing ROS production, and disrupting membrane potential.	[199]
39	Na2SeO3	BSA/ SeNPs	chemical reduction method in the presence of the BSA	20–30	Escherichia coli (ATCC no. 25922), Escherichia coli (ATCC no. BAA-2471), Staphylococcus aureus (ATCC no. 25923)	BC	1 mg/mL	SeNPs achieved a 10-fold reduction for S. aureus.	[200]
40	SeO2	eADF4(κ16)/SeNPs PVA/ SeNPs	chemical reduction method in the presence of the spider silk protein eADF4(κ16) and PVA (Polyvinyl alcohol)	46	Escherichia coli	BC	8 ± 1 µg/mL 405 ± 80 µg/mL	The eADF4(κ16)-coated SeNPs demonstrated a much higher bactericidal efficacy against the E. coli, with a minimum bactericidal concentration (MBC) approximately 50 times lower than that of PVA/SeNPs.	[201]
41	Na2SeO3	mycogenic SeNPs SeNPs-CN	2 methods: a biogenic process using Penicillium chrysogenum filtrate and by utilizing gentamicin drug (CN) following the application of gamma irradiation	33.84 22.37	Staphylococcus aureus, Bacillus subtilis, Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae Fungi: Candida albicans	BC, FC	0.490 μg/mL 0.245 μg/mL	The synthesized SeNPs-CN possesses an encouraging antimicrobial potential with respect to the biogenic SeNPs against all examined microbes. Remarkably, SeNPs-CN showed antimicrobial potential toward 23.0 mm ZOI for Escherichia coli and 20.0 mm ZOI against Staphylococcus aureus. It also inhibited the expansion and invasion of C. albicans suggested the use of gentamycin as antifungal agent after the combination with the synthesized SeNPs.	[202]
42	Se (pellets)	SeNPs	Pulsed laser ablation in liquids	115	Escherichia coli, Staphylococcus aureus	BC	50 µg/mL	The pure selenium nanoparticles determined the minimal concentration required for ~50% inhibition of either E. coli or S. aureus after 24 h to be at least ~50 µg/mL.	[203]
43	H2SeO3	Green Orange Peel extract/SeNPs	Chemical reduction in the presence of BSA—stabilizer	18.3	S. aureus (ATCC 25923), S. epidermidis (ATCC 1228)	BS	4.94 μg/L	The SeNP sample demonstrated excellent antibacterial activity with an average diameter of inhibition zones of 20.0 mm and an MIC of 4.94 μg/L.	[124]
44	Na2SeO3	SeNPs	Bioorganic synthesis of SeNPs with the use of Penicillium corylophilum As-1 biomass filtrate, in presence of ascorbic acid as a reducing agent	29.1–48.9	Staphylococcus aureus ATCC 6538, Bacillus subtilis ATCC 6633, Escherichia coli ATCC 8739, Pseudomonas aeruginosa ATCC 9027	BS	9.37 μg/mL 18.75 μg/mL 37.5 μg/mL 37.5 μg/mL	The formed SeNPs showed a prominent antimicrobial activity at different concentrations against the pathogens Staphylococcus aureus, Bacillus subtilis, Pseudomonas aeruginosa and E. coli.	[132]
45	SeO2	Penicillium expansum/SeNPs	biosynthesis with Penicillium expansum ATTC 36200	4–12.7	Bacillus subtilis ATCC 6051, Staphylococcus aureus ATCC 23235, Escherichia coli ATCC 8739, Pseudomonas aeruginosa ATCC 9027 Fungi: Candida albicans ATCC 90028, Aspergillus fumigatus RCMB 02568, A. niger RCMB 02724	BS, FS	62.5 μg/mL 62.5 μg/mL 125 μg/mL 125 μg/mL 125 μg/mL 125 μg/mL 125 μg/mL	The inhibitory effect against Gram-positive bacteria was more pronounced than against Gram-negative bacteria and fungi.	[149]
46	Na2SeO3	Chitosan/SeNPs	chemical reduction	77	Streptococcus mutans	BS	128 and 64 µg/mL	The comparison between the treated and untreated groups showed that combining therapy with SeNPs and PDT markedly decreased colony-forming units of one-day-old S. mutans biofilm.	[204]
47	SeO2	SeNPs	solvothermal method using Moringa oleifera leaf extract as a reducing agent	82.86	Listeria innocua ATCC 33090, Bacillus cereus ATCC 10876, Escherichia coli ATCC 43888, Salmonella typhimurium ATCC 14028	BS	100 μg/mL	Zones of inhibition were observed only in S. typhimurium (12.5 ± 0.5 mm), E. coli (10.1 ± 0.7 mm) and B. cereus (9.8 ± 0.7 mm).	[167]
48	Na2SeO3	SeNPs	green synthesis using ascorbic acid as a reducing agent and methanolic extract of Calendula officinalis L. flowers as a stabilizer	40–60	Serratia marcescens, Enterobacter cloacae, Alcaligenes faecalis	BS	-	The antibacterial activity of the extract, AsAc, and Na2SeO3 was enhanced by producing the SeNPs, which significantly inhibited the growth of S. marcescens, E. cloacae, and A. faecalis bacterial strains.	[205]
49	Na2SeO3	SeNPs	Chemical reduction synthesis from extracts of three plants: Allium cepa (onion), Malpighia emarginata (acerola), and Gymnanthemum amygdalinum (boldo)	245–321	Streptococcus agalactiae, Staphylococcus aureus, S. aureus, Pseudomonas aeruginosa, Escherichia coli	BS	6.125 to 98 μg/mL	The antimicrobial activity and low hemolytic concentration indicate the possibility of use against Gram-positive bacteria, including multidrug-resistant ones, opening a wide variety of options for their application	[151]
50	SeO2	Algae/ SeNPs	Microwave-assisted synthesis of SeNPs	40	V. harveyi (PTCC 1755)	BS	200 μg/mL	The presence of different functional groups of Sargassum angustifolium on the surface of the algae-coated SeNPs might be responsible for the more effective reaction of these nanoparticles with the cell walls and/or membrane of V. harveyi.	[206]
51	Na2SeO3	SeNPs	chemical reduction	71	V. cholerae O1 ATCC 14035 strain	BS	50–200 μg/mL	SeNPs are safe as an antibacterial and antibiofilm agent against V. cholerae O1 ATCC 14035 strain.	[207]
52	Na2SeO3	SeNPs, NCT/GA, NCT/GA/Eug and NCT/GA/Eug/SeNPs	chemical reduction	9.7, 124.8, 132.6 and 134.2 nm	Escherichia coli, Staphylococcus aureus	BS; BC	15.0 μg/mL 20 μg/mL	The entire fabricated nanocomposite exhibited potent antibacterial activity and cell destruction capability within 5–10 h of exposure.	[208]
53	Na2SeO3	SeNPs	synthesis and purification, in the presence of pepper extract; chemical reduction method, plus microwave	79–90 nm	Escherichia coli ATCC BAA-2471, Staphylococcus aureus ATCC 4330	BS	72,2 μg/mL 85,1 μg/mL	Selenium nanoparticles were biocompatible and showed bacteriostatic activity	[152]
54	Na2SeO3	SeNPs	biosynthesized with a standard strain of C. albicans	38	Fungi: Candida albicans, Candida glabrata	FS	1 and 0.5 µg/mL	SeNPs showed much better fungistatic activity compared to itraconazole, amphotericin B and anidulafungin.	[209]
55	Na2SeO3	SeNPs	Biosynthesis from lactic acid bacteria (LAB)	56	Fungi: Candida and Fusarium species	FC	80–130 µg/mL	The LAB-SeNPs MFC was in the range of 80–130 µg/mL, which ensured the complete killing of all tested fungi.	[210]
56	Na2SeO4	SeNPs	Biosynthesis with standard strains of A. Flavus and C. albicans	37 and 38	Fungi: Candida and Aspergillus species	FS	0.5, and 0.25 μg/mL	The utilization of SeNPs at concentrations of 1, 0.5 and 0.25 μg/mL or in, some strains, even lesss than 0.125 μg/mL, resulted in zero growth of fungal agents.	[126]
57	Na2SeO3	SeNPs	“green” method using the Halomonas elongata bacterium	11	Fungi: Candida albicans	FS	-	The synthesized NPs in optimal situation stopped the growth of Candida albicans up to 72%.	[211]
58	Se (pellets)	Chitosan/SeNPs	laser ablation in liquids	100	Fungi: C. albicans TW17 and 6486 strains	FC, FS	3.5 μg/mL	Taken separately, SeNPs and CS have shown fungicidal properties, but when combined (CS-SeNPs), achieved a potent inhibitory effect against the mature biofilm in a dose–response manner.	[212]
59	Na2SeO3	SeNPs	biosynthesis with the leaf extract of Melia azedarach	74	Fungi: Fusarium mangiferae	FC	300 μg/mL	Biogenic selenium NPs are widely expected to be efficient and cost-effective treatments for fungal plant diseases.	[213]
60	Na2SeO3	SeNPs	green synthesis using extracts from A. glaucum leaves and C. officinalis flowers	8 and 133	Fungi: Fusarium oxysporum, Colletotrichum gloeosporioides	FS	0.25 mg/mL	It was observed that both SeNPs had antifungal activity against both plant pathogens at concentrations of 0.25 mg/mL and above. SeNPs-AGL demonstrated better antifungal activity and smaller size (approximately 8.0 nm) than SeNPs-COF (134.0 nm).	[214]
61	Na2SeO3	SeNPs	biosynthesis by Lactobacillus aci- dophilus ML1	46	Fungi: Fusarium culmorum, Fusarium graminearum	FC	100 mg/mL	Under greenhouse conditions, the wheat supplemented with BioSeNPs (100 mg/mL) experienced significantly incidence of crown and root rot diseases by 75% and considerably enhanced plant growth, grain quantity and quality by 5–40%.	[215]
62	SeCl4	SeNPs	biosynthesis using endophytic fungus Fusarium oxysporum	42	Fungi: Aspergillus niger	FS	8 mg/mL; diluted to 4, 2, 1, 0.5, and 0.25 mg/mL	SeNPs showed excellent antifungal and antisporulant activity against black fungus Aspergillus niger, which has become life-threatening to SARS-CoV-2 patients during the pandemic.	[127]
63	Na2SeO4	SeNPs	biosynthesis with the use of Aspergillus strains	64.8	Fungi: Aspergillus fumigatus, Aspergillus flavus	FS	0.5 µg/mL	The MIC of itraconazole and amphotericin B against A. fumigatus and A. flavus was 4 μg/mL, whereas the MIC values for treated samples with SeNPs have decreased to 0.5 μg/mL.	[216]
64	Na2SeO3	SeNPs	biosynthesis using the extract of Melia azedarach leaves	61	Fungi: Puccinia striformis	FS	30 mg/L	SeNPs at a concentration of 30 mg/L reduced the disease severity and enhanced the morphological, physiological, biochemical and antioxidant parameters.	[217]
65	Na2SeO3	PPE/SeNPs and NCT/PPE/SeNPs	Pomegranate peel extract (PPE) used for biosynthesis	9.4 85	Fungi: Penicillium digitatum	FC	22.5 15 mg/mL	NCT/PPE/SeNPs nanocomposite was the most effective and significantly exceeded the fungicidal action of standard fungicide. The direct treatment of fungal mycelia with NCT/PPE/SeNPs nanocomposite led to remarkable lysis and deformations of P. digitatum hyphae within 12 h of treatment.	[218]
66	H2SeO3	SeNPs	Biosynthesis by Bacillus megaterium ATCC 55000	41.2	Fungi: Rhizoctonia solani RCMB 031001	FS, FC	0.0625 and 1 mM	SeNPs improve morphological and metabolic indicators and yield significantly compared with infected control.	[219]
67	Na2SeO3	SeNPs	chemical reduction method with the use of the Trichoderma atroviride cell culture lysate	93.2–98.5	Fungi: Pyricularia grisea, Colletotrichum capsici, Alternaria solani on chili and tomato leaves	FS	50 μg/mL 100 μg/mL 100 μg/mL	The synthesized nanoparticles displayed excellent in vitro antifungal activity against Pyricularia grisea and inhibited the infection of Colletotrichum capsici and Alternaria solani on chili and tomato leaves.	[220]
68	Na2SeO3	bovine serum albumin (BSA)/ SeNP, ascorbic acid/)/ SeNP, chitosan/SeNP, glucose/SeNP	chemical reduction method	70–300	Staphylococcus aureus (ATCC 6538), Enterococcus faecalis (ATCC 29212), Bacillus subtilis (ATCC 6633), and Kocuria rhizophila (ATCC 9341), Escherichia coli (ATCC 8739), Salmonella sp. (NCTC 6017), Klebsiella pneumoniae (NCIMB 9111), Pseudomonas aeruginosa (ATCC 9027), Fungi: Candida albicans (ATCC 10231)	BS, BC, FC	100 μg/mL 100 μg/mL 200 μg/mL 200 μg/mL 400 μg/mL 400 μg/mL 200 μg/mL 400 μg/mL 25 μg/mL	Chitosan/SeNPs had greater antibacterial and antifungal activity than BSA/SeNPs and glucose/SeNPs. The MIC for Gram-positive bacteria was higher.	[221]
69	Na2SeO3	TiO2-nanotubes/ SeNPs, AgNPs or Ag2SeNP	electrolysis of Na2SO3	<10	Staphylococcus epidermidis	BS	-	Nanocomposite reduced bacterial growth and biofilm formation. In comparison with the non-modifed control, the TiO2-nanotubes/SeNPs surfaces showed a signifcantly higher coverage area with osteoblastic MG-63-cells.	[177]
70	Na2SeO3	TiO2-nanotubes/ SeNPs	Chemical reduction in presence of TiO2-nanotubes	<10	Escherichia coli, Staphylococcus aureus	BS	-	Samples reduced the density of E. coli by 94.6% and of S. aureus by 89.6% compared to titanium controls.	[178]
71	Na2SeO3	polycarbonate films/SeNPs	Chemical reduction by glutation	50–100	Staphylococcus aureus	BS		Polycarbonate films/SeNPs inhibited bacterial growth to 8.9% and 27% when compared with an uncoated polycarbonate surface after 24 and 72 h, respectively.

BC—bactericidal effect, BS—bacteriostatic effect, FC—fungicidal effect, FS—fungistatic effect.

Se nanospheres are described in a significant portion of the studies [117,121,122,123,168]. However, other forms of SeNPs are described in a number of works: nanowires, nanorods and nanotubes. The form of SeNPs depends on the method and conditions of synthesis (pH, the presence and nature of the conjugate) [112,222]. Nanowires have bacteriostatic activity, but their MIC is comparable to or ~4–16 times lower than that of spherical SeNPs [112,222]. Comparable or higher MICs against bacteria and fungi were also found for Se nanorods compared with spherical SeNPs [112,222]. The literature also describes selenium-containing nanotubular structures with antibacterial activity [221,222]. However, it is difficult to compare the data of these works with the rest, since it is not possible to accurately estimate the final concentration of SeNPs in the obtained composites. The works devoted to the synthesis of “true” Se nanotubes are few and describe their potential application in technology, for example, in the creation of photosensors or solar cells; there are practically no works on antimicrobial applications of Se nanotubes [223].

Using regression analysis, it was found that the smaller the size of the selenium nanoparticles, the lower the necessary concentration of selenium nanoparticles for effective inhibition of bacterial growth (Figure 6b–d). Graphs are described by the following equations: y = 0.35x + 31.75 for the bacterium E. coli; y = 1.8x + 4.55 for the bacterium B. subtilis; and y = 0.19x + 34.65 for the bacterium S. aureus. For the bacterium B. subtilis, the regression coefficient was 1.8 (Figure 6c); for the bacterium E. coli, it was 0.35 (Figure 6b); and for the bacterium S. aureus, the lowest value was 0.19 (Figure 6d). In other words, a more efficient relationship between size and MIC was observed for B. subtilis than for E. coli and S. aureus.

A number of studies have shown that SeNPs have different antibacterial activities against Gram-positive and Gram-negative bacteria. A more pronounced antibacterial effect of SeNPs against Gram-negative bacteria compared to Gram-positive bacteria was shown. This property is of particular interest because, at present, among the bacteria that cause bacteremia, including sepsis, the proportion of Gram-negative bacteria is significantly increasing [224].

3.3. Dependence of the Minimum Inhibitory Concentration of Selenium Nanoparticles on Their Size in the Study of Antifungal Activity

Data were analyzed not only on the antiviral and antibacterial but also on the antifungal effect of selenium nanoparticles. Many more research papers have been devoted to the antifungal effect of selenium nanoparticles than to the antiviral effect; however, this effect is less than the antibacterial effect. In most fungal studies, the following species are used: Candida [126,150,202,209,210,211,212] and Fusarium [210,213,214,215]. Apart from these, the following fungal species are used: Colletotrichum [214,220], Puccinia [217], Aspergillus [127,216], Cryptococcus [150], Penicillium [218], Rhizoctonia [219], Pyricularia [220] and Alternaria [220]. Data on articles taken for analysis are also presented in Table 2.

Figure 7 shows the dependence of the minimum inhibitory concentration on the size of the nanoparticles. Using regression analysis, we can conclude that the smaller the size of the nanoparticles, the lower the value of the minimum inhibitory concentration (dependence equation y = 1.39x − 40.11). The graph shows the methods by which selenium nanoparticle synthesis was obtained. Most of the analyzed results use nanoparticles obtained by biological synthesis. We have presented research papers that use physical synthesis methods (laser ablation, gamma irradiation) to obtain selenium nanoparticles to study their antifungal effect. The nanoparticles used in these articles are usually spherical, and their size varies from 20 to 130 nm.

4. Mechanisms of Selenium Nanoparticle Antimicrobial Action

We decided to present the mechanisms of the antibacterial action of selenium nanoparticles in the form of a list (see below) and in the form of a diagram (Figure 8a).

(1)

Degradation of proteins due to the bactericidal action of selenium nanoparticles [112].

(2)

Slow emission of selenium ions from the surface of nanoparticles can lead to their interaction with -SH, -NH or -COOH functional groups of proteins and enzymes and the subsequent loss of their tertiary and quaternary structure and functions [125].

(3)

SeNPs contribute to the inactivation of the natural mechanisms of membrane transport of ions and nutrients through the cell walls, which blocks the vital activity of the cell [225].

(4)

Hyperproduction of ROS, disturbance of membrane potential, and depletion of internal ATP [199].

(5)

Inhibition of the activity of the dehydrogenase enzyme, as well as destruction of the integrity of the cell membrane [125].

(6)

Inhibition of the ability of bacteria to attach to the surface and form bacterial films [146].

(7)

Photocatalytic action against bacteria [226].

Thus, SeNPs can potentially be candidates for antibacterial substitutes and additives against antibiotic-resistant bacteria. Antimicrobial NPs can damage bacterial cells through multiple pathways. This multimodal antimicrobial behavior makes nanoparticles attractive, as bacteria are expected to have difficulty developing resistance to multiple forms of attack [227]. Researchers have also found that the viability of eukaryotic cells is preserved under the effective antibacterial action of selenium NPs [199].

In the case of the bacteriostatic action of selenium nanoparticles, the activity of the dehydrogenase enzyme is inhibited, and the integrity of the cell membrane is destroyed. This effect was observed when using selenium nanoparticles stabilized with arabinogalactan polysaccharide [125]. Researchers suggest possible mechanisms of the antibacterial action of selenium nanoparticles, which are triggered by the contact of the nanoparticle with a living cell.

In particular, this is the hyperproduction of ROS on the surface of nanoparticles, followed by a cascade of the LPO (lipid peroxidase) reaction, damage to cell membranes and organelles, blocking of the transcriptional gene and activation of apoptosis genes, as well as impaired synthesis of a number of cellular proteins and enzymes. In addition, the adhesion of nanoparticles on the cell surface can be accompanied by depolarization of the cell membrane, destruction of its integrity and, subsequently, cell death [125]. In the case of the combined bacteriostatic and bactericidal action of selenium nanoparticles, the ability of bacteria to attach to the surface and form bacterial films is presumably inhibited. This conclusion was made in the study of selenium nanoparticles with a silver shell [146]. For convenience, some mechanisms are shown schematically in Figure 8a,d.

Antifungal mechanisms includes antibiofilm activity [221,228], ROS generation and oxidative stress (with the addition of antifungal drug ketoconazole) [229] and influence on expression of fungicidal drug resistance genes [230] (Figure 8b).

The antiviral action of SeNPs is realized through several mechanisms: disruption of the functioning of viral capside proteins (in particular, hemagglutinin and neuraminidase activities of influenza virus), blocking of the virus-induced activation of the AKT-p52-Caspase3-dependent proapoptotic pathway, inhibition of viral replication in the host cell and enhancement of the action of antiviral drugs [183,184,187] (Figure 8c).

5. Methods for Studying the Characteristics of Selenium Nanoparticles

To describe the physicochemical characteristics of selenium NPs, a number of methods are usually used in the analyzed literature. Basically, in all articles, data on morphology, size and elemental composition are given.

Various microscopic methods are used to characterize the morphology of NPs. The most common is transmission electron microscopy (TEM) [231], and rarely atomic force microscopy (AFM) [232], scanning tunnelling microscopy (STM) [233] or scanning electron microscopy (SEM).

To characterize the sizes of NPs, the dynamic light scattering (DLS) method is most often used [234]. The method makes it possible to measure the hydrodynamic radius of nanoparticles, that is, the size of the NPs themselves and their solvate shell. The less-commonly used CPS Disc Centrifuge method allows estimation of the size of nanoparticles; however, with sizes less than 7 nm, the procedure can take several hours. Often, the size distribution of NPs is calculated using photographs or reconstructions obtained using microscopy. Differential centrifugal sedimentation (DCS) [235], particle size mobility scanning (SMPS) [236] and ion occlusion scanning (SIOS) are relatively inexpensive methods for determining particle size based on the Coulter counting principle [237]. The rarely used nanoparticle tracking analysis (NTA) method provides information on the diffusion of nanoparticles and their size [238].

A large number of methods are used to characterize the elemental composition of NPs. It should be noted that in biological applications, there are no NPs consisting of selenium oxide, and this greatly simplifies the task, since for most nanoparticles from other elements, it is necessary to prove the absence or presence of oxides [239]. Selenium oxide is soluble in water. When the surface of a selenium nanoparticle is oxidized, selenium oxide goes into solution, and the surface again consists of selenium atoms. The process continues until the complete dissolution of the selenium NP. To characterize the chemical composition, energy dispersive spectroscopy (EDX) [240] is usually used; this is very convenient since this method is usually integrated into modern transmission electron microscopes. X-ray photoelectron spectroscopy (XPS) is also often used [241]. In addition, the crystal structure of nanoparticles is often studied using the X-ray diffraction (XRD) method [242]. Selenium nanoparticles with impurities and conjugates are usually characterized with absorption spectroscopy in the UV–visible region of the spectrum [243] and Fourier transform IR spectroscopy (FTIR) [244,245].

Sometimes, differential scanning calorimetry and the Brunauer–Emmett–Teller (BET) method [246] are used to characterize NPs; these methods are used to study the surface area and rheological properties of NPs. Modulation interference microscopy (MIM) is used to study the spatial distribution of nanoparticles inside a polymer matrix [247]. The stability of NP colloids in a solvent is studied by measuring the zeta potential [227].

6. Cytotoxicity to Eukaryotic Cells

In addition to effective antimicrobial activity, it is also important to determine the safety of selenium nanoparticles for eukaryotic cells. This is a fundamental point that will allow the use of selenium nanoparticles in clinical practice. Zeraatkar et al. proved that selenium nanoparticles do not exhibit cytotoxicity to mouse fibroblasts (3T3 cell line) up to a concentration of 64 μg/mL, while the minimum inhibitory concentration is 4–8 μg/mL for Pseudomonas aeruginosa and Acinetobacter baumannii bacteria [117]. In another work by Jason Hou et al., it was shown that at concentrations from 2 to 16 μg/mL, no cytotoxicity was observed for osteoblast precursor cells (MC3T3-E1 osteoblast precursor cell line), which is important, while at concentrations of 4 μg/mL and more, the growth of the bacterium Porphyromonas gingivalis was inhibited [114].

In a published article [191], using selenium nanoparticles synthesized by a biogenic method, it was found that the inhibitory concentrations (IC50 is the concentration sufficient to inhibit the viability of 50% of cells) of SeNPs were 233.08 and 849.21 µg/mL for normal kidney cells and liver cells, respectively. Thus, normal liver cells showed greater viability to selenium nanoparticles compared with kidney cells. Importantly, the minimum inhibitory concentration of such nanoparticles against bacteria of the genera Salmonella, Klebsiella and Escherichia is 25–200 µg/mL, which is much lower than the concentration of cytotoxicity for the studied normal cell lines.

Importantly, the potential application of selenium nanoparticles lies precisely in their selective cytotoxicity; that is, nanoparticles show effective cytotoxicity for cancer cells and are safe for normal cells. For example, an article [131] was published in which the effective concentration for the antiproliferative activity of HeLa cells is 5.5 µg/mL, while the MIC for E. coli and S. aureus bacteria is 50 µg/mL. Thus, we can speak of effective inhibition of both the growth of cancerous and bacterial cells.

Moreover, a study was conducted and published in our laboratory that showed that selenium nanoparticles can have a cytoprotective effect on neuroglial cells of the cerebral cortex during ischemia/reoxygenation [48]. At concentrations as low as 3 µg/mL, selenium nanoparticles inhibit the hyperproduction of ROS in cells. The experiments also used a complex of selenium NPs with taxifolin (a flavonoid that lacks the “high dosage effect” that occurs in selenium NPs), while at a concentration of 10 µg/mL, the Se-TAX complex inhibits ROS hyperproduction and does not have toxicity on brain cells [48].

SeNPs are less toxic in vivo than other organic and inorganic (selenite) sources of Se [248]. This fact makes SeNPs attractive for biomedical applications. However, a number of experiments have shown that concentrations of SeNPs above 2 mg/kg can cause Se toxicity in mammals. [249]. Manifestations of toxicity at concentrations below 5–30 mg/kg according to the WOS standard require the substance to be classified as Toxicity class I–II. In addition, SeNPs (5 μM) exhibit acute toxicity to marine unicellular algae, which makes products based on SeNPs potentially hazardous to the environment [250]. SeNPs have comparable or even greater toxicity against microorganisms than metal NPs, for example, CuNPs [251]. The average MIC/MBC CuNPs against different strains of Escherichia coli and Staphylococcus aureus are ~210/235 and ~140/160 μg/mL, respectively [252]. For SeNPs, these values can reach <10 μg/mL and <20 μg/mL for MIC and MBC, respectively [114]. The inhibitory concentration for fungi of CuNPs is 13–22 μg/mL [253], which is comparable to or higher than that of SeNPs [150,209,212]. The toxic concentration of CuNPs for animals is 200 μg/kg, which is significantly higher than that of SiNPs, but lower than that of SiNPs [110,111,249]. CuNPs accumulate in the liver, inhibit CYP450 enzymes, and cause activation of pro-inflammatory reactions through the signaling pathway of NF-κB, MAPK, and STAT5 [254]. Thus, SeNPs have more pronounced antimicrobial properties than CuNPs, but may be more toxic against eukaryotes. These facts require caution in further biomedical developments using SeNPs.

7. Biomedical Applications

SeNPs can be used not only as antibacterial agents, but also as therapeutic agents for various pathologies. A detailed review of the biomedical applications of SeNPs can be found in [130,255]. Briefly, potential medical applications of SeNPs include cancer therapy (lung carcinoma, breast, liver, bone or kidney cancer, melanoma, etc.) [156,160,256,257,258,259], protection against poisoning (arsenic, patulin) [260,261], consequences of oxidative stress [157,256], therapy of diabetes mellitus I (oral delivery of insulin, relief of the consequences of hyperglycemia) [262,263,264] and Alzheimer’s disease [265]. In addition to the antimicrobial action, SeNPs have antiparasitic activity, which has been shown against protozoa (Leishmania, Promastigote, Giardia duodenalis, Toxoplasma) [266,267,268,269], tapeworms (Cystic echinococcus, Echinococcus granulosus) [270,271] and roundworms (Trichinella) [272].

8. Conclusions

Today, the problem of antimicrobial resistance is acute. A potential approach that can solve this problem is the use of selenium nanoparticles for antimicrobial activity against viruses, bacteria and fungi. That is why, in recent years, the interest of the scientific community in this topic has grown significantly. Selenium nanoparticles are especially attractive because of their relatively simple and inexpensive synthesis, as well as their low cytotoxicity for eukaryotic cells. Unfortunately, the chronic cytotoxicity of SeNPs has been little studied; therefore, in the future, it is necessary to carefully and thoroughly investigate this issue. It is expected that the development of scientific research in this area will effectively solve the problem of antimicrobial resistance in the near future. We consider that, in practical terms, it will be especially interesting to develop nanocoatings and nanocomposites with antibacterial properties based on SeNPs. It is probably worth focusing especially on antiviral research due to its potentially high threat. Recently, the number of publications on antiviral properties of SeNPs has been growing.